Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Date:7/24/2008

PITTSBURGH, July 24 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, August 6, 2008, at 10:30 a.m. ET to provide a review of the second quarter ended June 30, 2008. The company will release its financial results before the market opens August 6.

The dial-in number to access the August 6 call is 877-741-4241 or 719-325-4787 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 8142044.

To access a live webcast of the August 6 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately seven days.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
2. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
3. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
4. Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
5. Mylan Wins Generic Prilosec(R) Patent Litigation
6. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
7. Mylan Announces Final FDA Approval for Zaleplon Capsules
8. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
9. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... Montclair, NJ (PRWEB) , ... April 24, 2017 , ... ... International Plaza Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. ... all of our staff hearing this before they approach patients” about the course entitled ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to ... Navigate Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 ... CONTACT USA, and former member of the American Association of Christian Counselors. Rachel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical ... for the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed ... product advances towards regulatory and clinical phases. , "This is another important step ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: